Drug Profile
IT 901
Alternative Names: IT-901Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator ImmuneTarget
- Class Antineoplastics; Small molecules
- Mechanism of Action NF kappa B kinase inhibitors; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Multiple myeloma; Multiple sclerosis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA